In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
PREGNANCY: Pregabalin may slightly increase the risk of major congenital malformations if used in pregnancy. Patients should continue to use effective contraception during treatment and avoid use in pregnancy unless clearly necessary.
Pregabalin (Lyrica) and risk of abuse and dependence: new scheduling requirements from 1 April 2019 (UK)
As of 1 April 2019 in the UK, pregabalin is controlled under the Misuse of Drugs Act 1971 as a Class C substance and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Patients should be evaluated carefully for a history of drug abuse before prescribing pregabalin and patients should be observed for development of signs of abuse and dependence.
Please login to view the rest of this drug profile.